Sometimes a penny stock does something that makes you sit up and take notice. VolitionRx Limited (VNRX) did exactly that on Thursday, with shares surging more than 100% in premarket trading after the diagnostics company posted a 112% year-over-year revenue jump in the first half of 2026, hitting $1.4 million.
That kind of growth is impressive for any company, but for a small-cap epigenetics firm, it's a signal that the pieces might finally be falling into place. Volition is working across three big diagnostic verticals: sepsis monitoring, human oncology detection, and companion animal health. Combined, those markets represent more than $26 billion in total opportunity. That's a lot of runway for a company whose stock was trading near its 52-week low of $0.32 just recently.
Sepsis: A Validation That Matters
The sepsis story is particularly compelling. Independent, peer-reviewed data published in Critical Care Medicine confirmed that Volition's Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in severe sepsis patients. That's not just a nice-to-have; it's clinical utility that could drive adoption.
This validation supports a $2.8 billion total addressable market for the assay. And Volition isn't waiting around. The company is gearing up to start recruitment in September 2026 for France's DETECSEPS evaluation, a government-backed study worth $7.3 million. That's real money and real endorsement.
On top of that, Volition has confirmed clinical correlation for its bedside finger-prick lateral flow prototype. If that works out, it could move sepsis testing out of centralized labs and into point-of-care settings, which would be a game-changer for speed and accessibility.
Cancer Detection: Catching It Early
In oncology, Volition published data showing its Capture-Seq platform can identify over 95% of Stage I and II early cancers with 95% specificity. Early detection is where the money is, and the company is eyeing an annualized $23 billion opportunity there.
But it's not just about the science; it's about getting paid. Volition is actively preparing a conditional reimbursement filing in France for its lung cancer test, targeting the end of 2026. The company has already had initial pre-submission meetings, so this is moving forward in a concrete way.
Veterinary and Partnerships: The Long Game
The veterinary side is also progressing. Volition has submitted a manuscript for its Nu.Q Vet feline lymphoma test. Once it's peer-reviewed and published, that study unlocks a $5 million contractual milestone payment. Not bad for a paper.
To support global distribution, Volition has transferred its Nu.Q NETs assay to Sysmex Corporation's platform. That's a big deal because Sysmex has a massive installed base of analyzers worldwide. The company also says it's in active discussions with more than twelve major liquid biopsy and diagnostic firms. Those conversations could lead to partnerships that dramatically expand reach.
VNRX Price Action: VolitionRX shares were up 100.47% at $0.68 during premarket trading on Thursday. The stock is trading near its 52-week low of $0.32, according to market data.
So what's the takeaway? VolitionRx is a penny stock with a lot of irons in the fire. The revenue growth is real, the clinical validations are meaningful, and the market opportunities are huge. But it's still a small company with a lot to prove. The next few months, with the DETECSEPS study starting and the reimbursement filing in France, will be telling. For now, the market is betting that this time, the science and the business are aligning.
